Description
PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH
Article: PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH
€2.42
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€2.42 Add to cart -
Article: Calendar of events
€2.42 Add to cart -
Article: Highlights in digestive oncology
€2.42 Add to cart -
Article: Calendar of events
€2.42 Add to cart
